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Abstract
Purpose: Although several therapeutic options for bladder cancer are available,the poor efficacy and palpable side effects are a major concern. Establishing a moreeffective intervention is urgently demanded. Glycolysis is considered a strategictarget and has been often investigated in various cancers. Particularly,2-deoxyglucose (2DG), a glycolysis inhibitor, has been intensely studied and shownto be encouraging and promising. Accordingly, we investigated how targetingglycolysis with 2DG would be effective on bladder cancer cells. Methods: Bladdercancer 5637 cells were employed and cell viability was determined by MTT assay.To explore the anticancer mechanism of 2DG linked to glycolysis, two glycolyticparameters of hexokinase (HK) activity and ATP synthesis, metabolic signalingpathways, and induction of apoptosis were examined. Whether 2DG may potentiateseveral chemotherapeutic drugs being clinically used was also assessed for itspossible chemosensitizing effect. Results: A dose-dependent study of 2DG showeda 23-80% reduction in cell viability.  HK activity and cellular ATP level weredecreased by ~46% and ~56% with 2DG, respectively, indicating the glycolysisinhibition. AMP-activated protein kinase was activated while protein kinase Bwas inactivated and also mammalian target of rapamycin was inhibited with 2DG.These modulations would lead to the growth cessation and the cell viabilityreduction. In fact, the down-regulation of anti-apoptotic bcl-2 and theup-regulation of pro-apoptotic Bax in 2DG-treated cells indicated induction ofapoptosis. Moreover, chemotherapeutic drugs with poor cytotoxic activity wereselectively sensitized with 2DG, resulting in a significantly improved cell viabilityreduction. Conclusion: 2DG has anticancer activity on bladder cancer cells and itsanticancer mechanism involves the glycolysis inhibition, the modulations of certainsignaling pathways, and induction of apoptosis. Additionally, 2DG has achemosensitizing effect when combined with drugs. Thus, targeting glycolysis with2DG appears to be an alternative, viable therapeutic approach to bladder cancer.
Keywords: 2-deoxyglucose, Anticancer, Chemosensitization, Glycolysis, Bladdercancer
1. IntroductionBladder cancer is the second most commongenitourinary malignancy with high morbidity andmortality rates in the United States.1 Approximately74,000 new cases were diagnosed and nearly 16,000patients died in 2015.2 Among several availabletherapeutic options for bladder cancer, intravesicaladministration of Bacillus Calmette-Guerin (BCG) is themost effective immunotherapy for superficial bladdercancer and carcinoma in situ (CIS).3 This therapy hasbeen shown to alter disease progression, reduce
recurrence, and increase survival.4 However, thetherapeutic benefits of BCG are sometimes outweighedby its severe side effects, limiting its use in clinicalpractice.3,4 One approach for establishing a safer, moreeffective therapeutic modality with fewer side effects isto disrupt the proliferative mechanism of bladder cancersubstantially controlled by glycolysis.The growth and development of tumor cells (as well asnormal cells) must fulfill essential and critical cellular
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requirement, i.e. energy (ATP) metabolism. All kinds ofcells require energy for cellular maintenance, activity,proliferation, and development. Peculiarly, cancer cellshave been shown to preferentially depend on theinefficient glycolytic pathway (instead of TCA cycle) forATP production (generating only 2 ATP moles/glucose)even in the presence of sufficient oxygen.5 This is knownas the “Warburg effect”6 where cancer cells exhibit anextremely (~30-fold) higher rate of glycolysis comparedto normal cells utilizing the highly efficient TCA cycle(generating 36 ATP moles/glucose).7 The exact reasonfor this phenomenon is unknown but it could beattributed to the poor vasculature development withinsufficient supplies of oxygen and nutrition in cancercells.6 In fact, as targeting glycolysis for cancer treatmenthas been explored as a feasible therapeutic approach,8,9a blocking of the glycolytic pathway may indeed have asignificant impact on bladder cancer cell proliferation.In particular, the glucose analog, 2-deoxyglucose (2DG),has been studied as a potential anticancer agent due toits ability to inhibit glycolysis via the hexokinase step.5,10Multiple preclinical (in vitro and in vivo) studies showedthe efficacy of 2DG on several cancer cells such asleukemia, cervical cancer, breast cancer, prostate canceretc., leading to the reduction in their cellgrowth/viability.11,12 2DG has been reported to have thesensitizing cytotoxic effects when combined withchemotherapeutic drugs or radiation in colon, breast,ovarian, and pancreatic cancers.13,14,15 Additionally,2DG in combination with chemotherapeutic drugs alsodemonstrated antitumor effects on osteosarcoma, lung,breast, and prostate cancers in the nude mousexenograft models.16,17 These anticancer/antitumoreffects of 2DG are believed to be primarily due to themetabolic stress or cell death induced by the inhibitionof glycolysis.  Moreover, radiotherapy with 2DG inPhase I/II clinical trials on cerebral glioma showed theimproved efficacy and was well tolerated by patients.18Accordingly, we investigated if targeting glycolysis with2DG would effectively control the proliferation ofbladder cancer cells in vitro and also explored itsunderlying mechanism, focusing on glycolysis, metabolicsignaling pathways, and apoptosis. This study suggeststhat 2DG would be an anticancer agent as well as anadjuvant agent (to be combined with chemotherapeuticdrugs), offering a viable therapeutic option for bladdercancer. More details are described and discussed herein.
2. Methods and Materials
2.1. Cell cultureThe human bladder cancer 5637 cells were obtainedfrom the American Type Culture Collection (Manassas,VA).  Cells were cultured in RPMI-1640 mediumsupplemented with 10% fetal bovine serum, penicillin(100 units/ml), and streptomycin (100 g/ml). Forexperiments, cells were seeded in 6-well plates or T-75
flasks at the initial cell density of 2 x 105 cells/ml andtreated with given agents/drugs. Cell viability was thendetermined at specified times by MTT assay below.
2.2. MTT assayMTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay was used to determine cell viabilityfollowing the vendor’s protocol (Sigma-Aldrich, St. Louis,MO). Briefly, MTT reagent (1 mg/ml) was added to cells(in each well) in the 6-well plate, which was incubatedfor 3 h. After discarding MTT reagent, dimethyl sulfoxide(DMSO) was added to each well to dissolve the formazancrystals (purple). Absorbance of formazan solution wasread in a microplate reader, and cell viability wasexpressed by the % of sample readings relative to thecontrol reading (100%).
2.3. Hexokinase (HK) assayHexokinase (HK) activity was determined by the HKColorimetric Assay Kit (Biovision, Milpitas, CA) followingthe manufacturer’s protocol with minor modifications.Control or agents-treated cells were lysed in HK bufferprovided and supernatant (cell lysates) was obtained bycentrifugation. The NADH standards and cell lysates (20µg per sample) were prepared in the 96-well plate andthe reaction was started by the addition of reaction mix(containing substrate).  Immediately the plate wasplaced in a microplate reader and the absorbancechanges with time were monitored at 450 nm for 20 minwith 5-min intervals.  All readings were calculated andnormalized and then HK activity was expressed by the %of sample activity relative to the controls (100%).
2.4. Determination of cellular ATP levelThe cellular ATP level was determined using the ATPColorimetric Assay Kit (Biovision, Milpitas, CA) followingthe vender’s protocol. Cells (2 x 105 cells/ml) in the6-well plate were first lysed in ATP assay buffer and celllysates were deproteinized with HClO4 and neutralizedwith KOH. The ATP standards and samples (50 µl persample) were prepared in the 96-well plate and thereaction was started by the addition of reaction mixture.The plate was then incubated at room temperature for30 min in the dark. Absorbance (OD) at 570 nm wasread on a microplate reader and ATP content wascalculated by applying the sample readings to the ATPstandards. The ATP level was then expressed by the % ofsample readings relative to the controls (100%).
2.5. Western blot analysisBriefly, cell lysates (10 µg) of control or 2DG-treatedcells were resolved on 10% SDS-polyacrylamide gelelectrophoresis and transferred to a nitrocellulosemembrane. The blot (membrane) was incubated withthe primary antibodies against anti-phospho-AMPK,anti-phospho-Akt, anti-phospho-mTOR, anti-bcl-2, oranti-Bax (Santa Cruz Biotechnology, Santa Cruz, CA) for90 min with agitation, followed by incubation with theappropriate secondary antibody conjugates for 30 min.
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The specific immunoreactive protein bands weredetected by chemiluminescence following the manufacturer’s protocol (Kirkegaard and PerryLaboratories, Gaithersburg, MD).
Figure 1: Dose-dependent effects of 2DG on 5637 cell viability. Cells were cultured with varying concentrations (0-20 mM) of2DG and cell viability at 72 h was assessed by MTT assay. Cell viability was then expressed by the % of viable cells relative tothat in control (100%). All data represent mean ± SD (standard deviation) from three independent experiments and (*p <0.05 compared with controls).
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Figure 2: Effects of 2DG on HK activity and cellular ATP level. After cells were cultured with 2DG (15 mM) for 72 h, HKactivity and ATP level were determined separately and were expressed by the % of HK activity and ATP level relative torespective control (100%). The data are mean ± SD from three separate experiments (*p < 0.05 compared with controls).
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Figure 3: Effects of 2DG on specific signaling regulators. After cells were treated with 2DG (15 mM) for 72 h, the status of thekey regulators in the specific signaling pathways such as p-AMPK, p-Akt, and p-mTOR was analyzed by Western blots. Theelevated phosphorylation level of p-AMPK with 2DG indicates AMPK activation, while the reduced phosphorylation levels ofp-Akt and p-mTOR indicate their inactivation. Beta-actin is used as a protein loading control. Further details are described inthe text.
Figure 4: Effects of 2DG on apoptosis regulators. Protein expressions of bcl-2 and Bax in control and 2DG-treated cells at 72 hwere analyzed using Western blots. Autoradiogram shows the decreased bcl-2 and the increased Bax expressions in2DG-treated cells, indicating induction of apoptosis. Beta-actin is used as an internal control.
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Figure 5: Chemosensitizing effect of 2DG. (A) Cells were treated with 2DG (5 mM), DOX (5 ng/ml), GEM (20 nM), 5FU (5
g/ml), CPL (100 M) or MMC (300 nM) for 72 h and cell viability was determined. (B) Cells were also treated with all thesedrugs combined with 2DG at given concentrations (as indicated) for 72 h and cell viability was determined. Cell viability wasthen expressed by the % of viable cells relative to that in control (100%). All data are mean ± SD from three separateexperiments (*p < 0.05 compared with controls).
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2.6. Statistical analysisAll data were obtained from at least three independentexperiments and presented as mean ± standarddeviation (SD).  Statistical differences between groupswere assessed with either one-way analysis of variance(ANOVA) or the unpaired Student’s t test. Values of p <0.05 were considered to indicate statistical significance.
3. Results
3.1. Dose-dependent effect of 2DG on 5637 cell
viabilityTo examine if 2DG may have anticancer effect on 5637cells, a dose-dependent study was performed to assesscell viability that determines the % of viable cellsfollowing 2DG treatment. It should be noted that actualeffects of 2DG would be seen when its concentrations go>10 mM because culture medium contains ~11 mMglucose, which could compete with 2DG. Cells werecultured with varying concentrations (0-20 mM) of 2DGfor 72 h and cell viability was assessed by MTT assay.The results showed that 2DG led to a 23-80% reductionin cell viability once its concentrations exceeded 10mM) (Figure 1). Thus, 2DG appears to have anticanceractivity, significantly reducing cell viability. As 15 mM of2DG is proximate to its IC50 (50% inhibitoryconcentration), this concentration was then used in therest of our study.
3.2. Effect of 2DG on glycolysisWe next examined if 2DG-induced cell viabilityreduction could be associated with the glycolysisinhibition because 2DG is known to specifically inhibitHK involved in the irreversible committed step inglycolysis.19 Cells treated with 2DG for 72 h weresubjected to HK assay. Compared to controls (100%), HKactivity declined to ~54% (i.e. a ~46% activity loss)with 2DG treatment (Figure 2). ATP assay revealed thatthe cellular ATP level was also down to ~44% (i.e. a~56% reduction), due to HK inactivation by 2DG (Figure2). Thus, the reduction in HK and ATP levels by 2DGindicates the inhibition of glycolysis, eventually leadingto the growth cessation and the cell viability reduction.
3.3. Effects of 2DG on signaling pathwaysAs energy (ATP) reduction/depletion due to theglycolysis inhibition has been shown to affect metabolicsignaling pathways,20 cells treated with 2DG for 72 hwere analyzed for three key regulators using Westernblots. Such analysis revealed that AMP-activated proteinkinase (AMPK)21 was highly phosphorylated (activated)while serine/threonine protein kinase B (Akt)22 wasdephosphorylated (inactivated) by 2DG (Figure 3).Moreover, mammalian target of rapamycin (mTOR),working with Akt to promote cell proliferation,23 wasalso dephosphorylated or inactivated (Figure 3). Thus,activation of AMPK concomitant with inactivation of Aktand mTOR by 2DG suggest that 5637 cells may
ultimately undergo cell death as it has been shown incertain cancer cells.21,22,23,24
3.4. Induction of apoptosis by 2DGIt is also important to address if cell death induced by2DG might be linked to apoptosis. Cells treated with 2DGfor 72 h were analyzed for the status of two keyapoptosis regulators, anti-apoptotic bcl-2 andpro-apoptotic Bax,25 using Western blots. Analysisrevealed that expression of bcl-2 was reduced ordown-regulated while that of Bax was enhanced orup-regulated following 2DG treatment (Figure 4). Thus,these results indicate that 2DG could induce apoptosis in5637 cells.
3.5. Chemosensitizing effect of 2DGChemotherapy is yet one of the most commontherapeutic options for cancer patients despite the poorefficacy with considerable side effects.26 We examined if2DG could sensitize chemotherapeutic drugs, whichwere being clinically used. Those drugs includeddoxorubicin (DOX), gemcitabine (GEM), 5-flurouracil(5FU), cisplatin (CPL), and mitomycin C (MMC). Cellswere treated with 2DG (5 mM), DOX (5 ng/ml), GEM (20nM), 5FU (5 g/ml), CPL (100 M) or MMC (300 nM) for72 h and cell viability was determined. Theconcentrations of these drugs used were the estimatedmaximum or above physiologically tolerable levels.Additionally, 5 mM (instead of 15 mM) of 2DG was usedbecause it showed little effect but might demonstrate itssensitizing effect on drugs. Such studies showed that2DG, DOX, GEM, and CPL alone had little effects, but 5FUand MMC alone led to a ~45% and ~55% cell viabilityreduction, respectively (Figure 5A). When these drugswere combined with 2DG at given concentrations, cellviability was significantly (~35-60%) reduced in allcombinations (Figure 5B). However, it should be advisedthat anticancer effects of 5FU and MMC alone were notsignificantly improved in combination with 2DG(2DG+5FU and 2DG+MMC): cell viability of ~55% with5FU and of ~45% with MMC alone was reduced to only~50% and ~40% with 2DG combination (i.e. a merely5% reduction), respectively. Hence, no significantpotentiating effect of 2DG was found when combinedwith 5FU or MMC. Therefore, 2DG appears to selectivelysensitize or potentiate chemotherapeutic drugs,resulting in the improved or greater cell viabilityreduction. This plausibly suggests that 2DG has a(selective) chemosensitizing effect.
4. DiscussionGlycolysis is the major metabolic pathway essential tocancer cells as described by the “Warburg effect”.6 Since2-deoxyglucose (2DG) can interrupt glycolysis,19 it hasbeen considered an anticancer agent capable ofinhibiting the growth and development of cancers.  Infact, anticancer effect of 2DG has been studied on a
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variety of cancer cells in vitro and in vivo.12,14,15,16 Wewere then tempted to study if 2DG might haveanticancer effect on bladder cancer cells, through thedisruption of glycolysis. Additionally, the anticancermechanism of 2DG was further explored, focusing onglycolysis and its related cellular/biochemical eventssuch as metabolic signaling pathways and apoptosis.A dose-dependent study showed that 2DG was indeedcapable of significantly reducing cell viability. To have abetter understanding of this 2DG-induced cell viabilityreduction, the effect of 2DG on glycolysis was examinedbecause 2DG is a known glycolytic inhibitor. Suchstudies showed that HK activity and cellular ATPsynthesis were significantly reduced by 2DG, indicatingthe inhibition of glycolysis. As a result, cellular energy(ATP) production would be critically reduced, eventuallyleading to a significant cell viability reduction (due tocell death).Actually, energy (ATP) depletion, due to glycolysisinhibition (by 2DG), is shown to have a substantialimpact on metabolic signaling pathways.20 In fact, wefound that AMPK and Akt, which were closely coupledwith energy metabolism, were activated and inactivatedby 2DG, respectively. AMPK is known as the masterenergy sensor that immediately responds to energydeficiency and halts glycolysis,21 while Akt acts oppositeto AMPK and is the key mediator of cell survival thatstimulates glycolysis.22 Both AMPK and Akt act asprotein kinases and must be phopsphrylated to becomeactive and functional.22,23 Activation of AMPK duringenergy deficiency has been shown to be cytotoxic to avariety of cancer cells including lung, prostate, stomach,liver, breast, and glial cancer cells in vitro.27 Incontrast, Akt is activated through phosphatidylinositol-3 kinase (PI3K) in response to several growthfactors and this activation can regulate metabolic andnuclear processes for cell survival by stimulatingglycolysis and inhibiting apoptosis.22,28 In short, AMPKtends to inhibit glycolysis and promote apoptosis, whileAkt stimulates glycolysis and inhibit apoptosis. Hence,AMPK and Akt can interact directly through twoopposed mechanisms21 and activation/inhibition ofthese two parameters would determine the cellularenergy (ATP) metabolism, an anabolic or catabolicprocess. Moreover, activation of AMP and inhibition ofAkt (due to ATP depletion) is also known to inhibit ordown-regulate mTOR, the master orchestrator of cellproliferation, which is a protein kinase promotingprotein synthesis and cell proliferation.23 Therefore,AMPK activation and Akt/mTOR inactivation induced by2DG in this study presumably lead to the growthcessation and ultimate cell death.Along with the glycolysis inhibition and the modulationsof metabolic signaling pathways through 2DG, 5637 cellswere found to ultimately undergo apoptosis, indicatedby specific modulations of bcl-2 and Bax.25 Thus,
2DG-induced cell viability reduction would most likelyresult from apoptosis.To find the clinical relevance of 2DG, we examined if2DG would have a chemosensitizing effect, capable ofimproving/potentiating the drug efficacy. Such studyshowed that the combination of 2DG and various drugs(except for 5FU and MMC) led to a significantlyimproved cell viability reduction, although individual2DG and drugs (except for 5FU and MMC) had onlynegligible effects. It is thus plausible that 2DG can bealso considered as a potential adjuvant agent that has aselective chemosensitizing effect on drugs, improvingthe drug efficacy.Lastly, it is important to address the safety of 2DG.Various animal and clinical studies reported that 2DGwas safe and relatively non-toxic in animals andhumans. For instance, the LD50 of 2DG was found to be
2 g/kg body weight for mice,29 and Phase I/II clinicalstudies on gliomas and Phase I studies on advanced solidtumors as well as prostate cancer showed no adverseeffects of 2DG with the improved antitumor effect foundin those patients.18,30,31 These clinical trials also involvedthe combinations of 2DG and chemotherapeutic drugs orradiation, which had been shown to have the betteroutcomes than monotherapy (2DG alone). Achemosensitizing effect of 2DG on several drugs seen inthis study may also imply an advantage of combinationtherapy (over monotherapy) for bladder cancer. Thus,2DG appears to be a safe, non-toxic agent that can beclinically used alone or combined with appropriatedrugs/agents or interventions.
5. ConclusionThe present study demonstrates that 2DG has anticanceractivity on bladder cancer 5637 cells and its anticancermechanism involves diverse cellular effects such as, cellviability reduction, glycolysis inhibition, modulations ofmetabolic signaling pathways, and induction ofapoptosis. Additionally, 2DG may have achemosensitizing effect on certain drugs and could beused as an adjuvant agent. Therefore, targetingglycolysis using certain glycolytic inhibitors (e.g. drugsand agents such as 2DG) could be an alternative, viabletherapeutic approach to bladder cancer. Further studiesare warranted.
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AcknowledgementWe would like to thank “Seize the Ribbon” for thegenerous support.
References1. Kamat AM, Hahn NM, Efstathiou JA, et al.Bladder cancer. Lancet. 2016;388(10061):2796-810.2. Seigel RL, Miller KD, Jemal A. Cancer statistics.CA Cancer J Clin. 2015;65:5-29.3. Shen Z, Shen T, Wientjes MG, et al. Intravesicaltreatments of bladder cancer: review. PharmRes. 2008;25:1500-10.4. Malmstrom PU. Intravesical therapy ofsuperficial bladder cancer. Crit Rev OncolHematol. 2003;47:109-26.5. Choi Y, Lee JH. The combination of tephrosinwith 2-deoxy-D-glucose enhances thecytotoxicity via accelerating ATP depletion andblunting autophagy in human cancer cells.Cancer Biol Ther. 2011;12:989-96.6. Warburg O. On the origin of cancer cells.Science. 1956;123:309-14.7. Gatenby RA, Gillies RJ. Why do cancers havehigh aerobic glycolysis? Nat Rev Cancer.2004;4:891-9.8. Pelicano H, Martin DS, Xu RH, et al. Glycolysisinhibition for anticancer treatment. Oncogene.2006;25:4633-46.9. Xu RH, Pelicano H, Zhou Y, et al. Inhibition ofglycolysis in cancer cells: a novel strategy toovercome drug resistance associated with
mitochondrial respiratory defect and hypoxia.Cancer Res. 2005;65:613-21.10. Zhong D, Xiong L, Liu T, et al. The glycolyticinhibition of 2-deoxyglucose activates multipleprosurvival pathways through IGF1R. J BiolChem. 2009;284:23225-33.11. Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz deAlmodovar C, et al. Inhibition of glucosemetabolism sensitizes tumor cells to deathreceptor-triggered apoptosis throughenhancement of death-inducing signalingcomplex formation and apical procaspase-8processing. J Biol Chem. 2003;278:12759-68.12. Wang L, Wang J, Xiong H, et al. Co-targetinghexokinase 2-mediated Warburg effect andULK1-dependent autophagy suppresses tumorgrowth of PTEN- and TP-53-deficiency-drivencastration-resistant prostate cancer.EBioMedicine 2016;7:50-61.13. Hernlund E, Strandberg Ihrlund L, Khan O, et al.Potentiation of chemotherapeutic drugs byenergy metabolism inhibitors 2-deoxyglucoseand etomoxir. Int J Cancer. 2008;123:476-83.14. Hernlund E, Hjerpe E, Avall-Lundqvist E, et al.Ovarian carcinoma cells with low levels ofβ-F1-ATPase are sensitive to combinedplatinum and 2-deoxy-D-glucose treatment. MolCancer Ther. 2009;8:1916-23.15. Coleman MC, Asbury CR, Daniels D, et al.2-deoxy-D-glucose causes cytotoxicity,oxidative stress, and radiosensitization inpancreatic cancer. Free Radic Biol Med.2008;44:322-31.16. Maschek G, Savaraj N, Priebe W, et al.2-deoxy-D-glucose increases the efficacy ofadriamycin and paclitaxel in humanosteosarcoma and non-small cell lung cancers
in vivo. Cancer Res. 2004;64:31-4.17. Tagg SL, Foster PA, Leese MP, et al.2-methoxyoestradiol-3,17-O,O-bis-sulpahamateand 2-deoxy-D-glucose in combination: apotential treatment for breast and prostatecancer. Br J Cancer. 2008;99:1842-8.18. Mohanti BK, Rath GK, Anantha N, et al.Improving cancer radiotherapy with2-deoxy-D-glucose: phase I/II clinical trials onhuman cerebral gliomas. Int J Radiati Oncol BiolPhys. 1996;35:103-11.19. Miccoli L, Oudard S, Sureau F, et al. IntracellularpH governs the subcellular distribution ofhexokinase in a glioma cell line. Biochem J.1996;313:957-62.20. Cheong JH, Park ES, Liang J, et al. Dualinhibition of tumor energy pathway by2-deoxyglucose and metformin is effectiveagainst a broad spectrum of preclinical cancermodels. Mol Cancer Ther. 2011;10:2350-62.21. Priebe A, Tan L, Wahl H, et al. Glucosedeprivation activates AMPK and induces cell
10 Valera et al.: Target glycolysis with 2-deoxyglucose in bladder cancer International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Valera et al. ISSN 2330-4049
death through modulation of Akt in ovariancancer cells. Gynecol Oncol. 2011;122:389-95.22. Lee YK, Park OJ. Regulation of mutual inhibitoryactivities between AMPK and Akt withquercetin in MCF-7 breast cancer cells. OncolRep. 2010;24:1493-7.23. Bolster DR, Crozier SJ, Kimball SR, et al.AMP-activated protein kinase suppressesprotein synthesis in rat skeletal muscle throughdown-regulated mammalian target ofrapamycin (mTOR) signaling. J Biol Chem.2002;277:23977-80.24. Lai E, Teodorp T, Volchuk A. Endoplasmicreticulum stress: signaling the unfolded proteinresponse. Physiology. 2007;22:193-201.25. Yip KW, Reed JC. Bcl-2 family proteins andcancer. Oncogene. 2008;27:6398-406.26. Zhang HH, Guo XL. Combinational strategies ofmetformin and chemotherapy in cancers.Cancer Chemother Pharmacol. 2016;78:13-26.
27. Kuhajda FP. AMP-activated protein kinase andhuman cancer: cancer metabolism revisited. IntJ Obes. 2008;32:S36-41.28. MacFarlane M, Robinson GL, Cain K. Glucose – asweet way to die: metabolic switchingmodulates tumor cell death. Cell Cycle.2012;11:3919-25.29. Landau BR, Lubs HA. Animal responses to2-deoxy-D-glucose administration. Proc SocExp Biol Med. 1958;99:124-7.30. Raez LE, Papadopoulos K, Ricart AD, et al. Aphase I dose-escalation trial of2-deoxy-D-glucose alone or combined withdocetaxel in patients with advanced solidtumors. Cancer Chemother Pharmacolo.2013;71:523-30.31. Stein M, Lin H, Jeyamohan C, et al. Targetingtumor metabolism with 2-deoxyglucose inpatients with castration-resistant prostatecancer and advanced malignancies. Prostate.2010;70:1388-94.
